The American biotechnology giant Moderna (NASDAQ: MRNA) stock hit a fresh 52-week low of $115.61 on Monday ahead of the FDA advisory committee meeting to decide whether to give approval to Moderna’s COVID-19 vaccine for young children.
Moderna was the first drugmaker with an experimental COVID-19 vaccine to begin clinical testing in humans in the U.S. Moderna’s vaccine is currently available only to people 18 and older.
Read more here - https://gulfbrokers.com/en/is-the-moderna-stock-a-bargain-ahead-of-fda-decision